首页> 美国卫生研究院文献>Vaccine: X >Responsiveness to basement membrane extract as a possible trait for tumorigenicity characterization
【2h】

Responsiveness to basement membrane extract as a possible trait for tumorigenicity characterization

机译:对基底膜提取物的响应性可能是致瘤性表征的特征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Immortalized cell lines used to produce vaccines are expected to be described in terms of their tumorigenicity. However, current in vivo tumorigenicity assays can be time-consuming and results can be equivocal, especially for weakly tumorigenic cells. Basement membrane extract (BME) derived from the Engelbreth-Holm-Swarm mouse tumor, such as Matrigel and Cultrex, consists of laminin, collagen IV, entactin, heparan sulfate, and proteoglycans, as well as biologically active peptides and growth factors. For nearly three decades, BME has been used in cancer research to enhance tumorigenicity assays (both tumor “take” as well as tumor growth are substantially improved). We assessed the feasibility of using BME to facilitate the evaluation of vaccine cell substrate tumorigenicity. Vero cells (WHO 10-87) were serially passaged and banked at every ten passages beginning with p140; for the present study, low-passage Vero cells (Vero LP, originating from cells banked at p140) and high-passage Vero cells (Vero HP, originating from cells banked at p250) were used. In addition, Vero TPX2 and Vero NM1, cell lines established from tumors formed in nude mice by Vero HP cells, as well as other cell lines relevant to vaccine production (HeLa, MDCK, 293, and ARPE-19), were assessed. Female adult athymic nude mice were injected subcutaneously with cells in the absence or presence of BME. We observed that the tumorigenicity of ARPE-19 cells as well as Vero cells below passage 258 (Vero LP and Vero HP; previously characterized as non-tumorigenic or weakly tumorigenic, respectively) was not enhanced by BME. In contrast, BME shortened the latency and decreased the tumor-producing cell dose of HeLa, 293, and MDCK cells as well as the tumorigenic Vero derivatives TPX2 and NM1. Thus, responsiveness to BME may reflect the status of the neoplastic process and possibly serve as a useful trait for better defining the tumorigenic phenotype of cells.
机译:用于生产疫苗的永生细胞系有望从其致瘤性方面进行描述。然而,当前的体内致瘤性测定可能是耗时的并且结果可能是模棱两可的,尤其是对于致癌性较弱的细胞而言。来源于Engelbreth-Holm-Swarm小鼠肿瘤(例如Matrigel和Cultrex)的基底膜提取物(BME)由层粘连蛋白,IV胶原,动蛋白,硫酸乙酰肝素和蛋白聚糖以及生物活性肽和生长因子组成。近三十年来,BME已用于癌症研究中以增强致瘤性分析(肿瘤的“摄取”和肿瘤的生长均得到了显着改善)。我们评估了使用BME促进评估疫苗细胞底物致瘤性的可行性。从p140开始,每十次传代Vero细胞(WHO 10-87)并倾斜。在本研究中,使用了低传代Vero细胞(Vero LP,起源于p140的细胞)和高传代Vero细胞(Vero HP,起源于p250的细胞)。此外,还评估了Vero TPX2和Vero NM1,以及由Vero HP细胞在裸鼠中形成的肿瘤建立的细胞系,以及与疫苗生产相关的其他细胞系(HeLa,MDCK,293和ARPE-19)。在不存在或存在BME的情况下,将雌性成年无胸腺裸鼠皮下注射细胞。我们观察到BPE没有使传代258以下的ARPE-19细胞以及Vero细胞的致瘤性(Vero LP和Vero HP;分别表征为非致瘤性或弱致瘤性)。相反,BME缩短了潜伏期并降低了HeLa,293和MDCK细胞以及致瘤性Vero衍生物TPX2和NM1的肿瘤发生细胞剂量。因此,对BME的反应性可能反映了肿瘤形成过程的状态,并可能充当有用的性状,以更好地定义细胞的致瘤表型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号